Evidence map›Paper›PMID 40699638›Full record

ReviewCurrent issues in molecular biology2025

The Role of Injectable Platelet-Rich Fibrin in Orthopedics: Where Do We Stand?

Fábio Ramos Costa, Sergio Augusto Lopes de Souza, Rubens Andrade Martins, Bruno Ramos Costa, Luyddy Pires, Alex Pontes de Macedo, Napoliane Santos, Stephany Cares Huber, Gabriel Silva Santos, André Kruel and 2 more

Abstract readReview
In one paragraph

Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fábio Ramos CostaDepartment of Orthopedics, FC Sports Traumatology, Salvador 40296-210, BA, Brazil.ORCID 0009-0003-0486-8114
Sergio Augusto Lopes de SouzaDepartment of Radiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-916, RJ, Brazil.ORCID 0000-0002-7901-4805
Rubens Andrade MartinsMedical School, Tiradentes University Center, Maceió 57038-000, AL, Brazil.ORCID 0000-0002-2513-9864
Bruno Ramos CostaMedical School, Zarns College, Salvador 41720-200, BA, Brazil.
Luyddy PiresDepartment of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.ORCID 0009-0007-0725-7940
Alex Pontes de MacedoDepartment of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.ORCID 0000-0003-4394-1209
Napoliane SantosDepartment of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.ORCID 0009-0002-8938-5498
Stephany Cares HuberDepartment of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
Gabriel Silva SantosDepartment of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
André KruelRegenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.ORCID 0000-0002-7415-3953
Márcia SantosNutritional Sciences, Metropolitan Union of Education and Culture, Salvador 42700-000, BA, Brazil.
José Fábio LanaDepartment of Orthopedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Injectable Platelet-Rich Fibrin (i-PRF) has emerged as a promising tool in regenerative medicine, particularly in orthopedics, due to its unique biological properties and ease of preparation. i-PRF is an autologous platelet concentrate derived through a simple, anticoagulant-free centrifugation process, resulting in a liquid matrix enriched with fibrin, leukocytes, and growth factors. These components promote tissue regeneration, angiogenesis, and anti-inflammatory responses, making i-PRF suitable for bone and cartilage repair as well as drug delivery systems. This review discusses the history, biological mechanisms, and clinical applications of i-PRF in orthopedics, highlighting its potential advantages over traditional platelet-rich plasma (PRP). Furthermore, we address the challenges and limitations of i-PRF, including drug stability, release control, and bioactive interactions, underscoring the need for further research to optimize its therapeutic efficacy.

Indexed as

anti-inflammatory therapyorthopedicsplatelet-rich fibrinregenerative medicinetissue regeneration

Identifiers

PMID40699638
PMCPMC12025550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.